Gut Barrier and Dysbiosis — Foundational Reference

The gut system is the second major constitutional factor in this clinical picture. It is tightly coupled to the CNS system through the gut-vagus connection and through continuous inflammatory signaling originating at the intestinal barrier. LPS translocation increases the inflammatory load while the compromised vagal anti-inflammatory pathway can no longer adequately brake it. This document describes the gut system on its own terms: its constitutional vulnerability, the established chronic barrier dysfunction, the iron-triggered collapse into a locked dysbiotic state, and the hepcidin-iron dynamic as a systemic expression of chronic inflammatory load. Interventions and clinical pathways are addressed in separate documents.

I. Constitutional Gut Vulnerability

The gut system did not arrive at its current state through a single event. It was constitutionally shaped before any diagnosable disease appeared.

Continuous antibiotic exposure from infancy through age 7 for recurrent ear infections depleted the gut microbiome during the critical developmental window for mucosal immune maturation and autonomic nervous system development. The commensals that should have established during that period did not. The regulatory immune capacity — mucosal tolerance, secretory IgA production, T-regulatory cell development — that develops in the presence of a healthy early microbiome was impaired from the start. The chronic mastoiditis visible on brain imaging from 2016 through 2025 is structural evidence of the severity of the early infectious burden.

The consequences of this early disruption compounded over decades. Seropositive RA diagnosed in 2008 — almost certainly active for years before diagnosis — maintained chronic systemic inflammation that subjected the mucosal barrier to sustained cytokine-driven stress throughout the subsequent decade. Microscopic colitis confirmed on biopsy in 2011 and 2015 documents active mucosal pathology during this period. The gut that helminthic therapy inherited in 2020 was already decades into a process of barrier dysfunction and immune dysregulation.

II. Intestinal Barrier Dysfunction — The Established Chronic Pattern

The intestinal barrier dysfunction in this patient is not a hypothesis — it is a documented, long-standing clinical pattern with multiple lines of supporting evidence.

The primary clinical signature is systemic inflammatory responses to food exposures — joint swelling and muscle pain within hours of ingestion — rather than local gastrointestinal symptoms. This pattern is consistent with antigen translocation across a compromised mucosal barrier driving systemic immune activation. It is not classical food allergy; it is barrier-mediated systemic inflammation operating through a different mechanism entirely.

Persistently elevated IgA (359-531 mg/dL, consistently above the reference range of 87-352 mg/dL across multiple years) is consistent with chronic mucosal immune activation. Celiac serology has remained persistently positive — TTG IgA elevated, deamidated gliadin antibodies elevated, endomysial antibody historically positive — despite negative histology across multiple biopsies. The seronegative biopsy pattern does not exclude ongoing mucosal immune activation; it reflects the limitations of biopsy sampling rather than absence of pathology.

Confirmed mucosal diagnoses include collagenous colitis on biopsy in 2011 and 2015, and active microscopic colitis with mucosal biofilm on the December 2025 colonoscopy. Microscopic colitis symptoms were absent from 2020 through early 2024 — the histological abnormality persisted throughout; it was the symptoms that resolved with helminthic therapy, not the underlying condition.

LPS Translocation and NF-κB Drive

The functional consequence of chronic barrier dysfunction is persistent low-level bacterial endotoxin (LPS) translocation into systemic circulation. LPS continuously stimulates TLR4 on macrophages. TLR4 activation feeds directly into NF-κB, driving transcription of TNF, IL-1β, IL-6, IL-18, and HMGB1 simultaneously. This mechanism operates independently of joint-specific RA pathology and provides a continuous systemic inflammatory drive that amplifies disease severity beyond what the underlying autoimmune process alone would produce.

This is not the cause of the RA. It is the engine that has been amplifying its severity and refractoriness throughout the clinical history — and it is the engine that the compromised vagal anti-inflammatory pathway can no longer adequately brake.

III. Hepcidin and Iron Absorption Dynamics

Hepcidin is a liver-derived peptide hormone that regulates systemic iron availability by blocking ferroportin, the primary cellular iron export channel. Under conditions of chronic inflammation, IL-6 and other cytokines drive sustained hepcidin upregulation through the STAT3 pathway. Elevated hepcidin traps iron in macrophages and intestinal enterocytes, blocking its release into circulation regardless of total body iron stores.

In a patient with decades of chronic autoimmune inflammatory activity, hepcidin upregulation is a persistent systemic feature — not a transient response to acute infection. The result is functional iron deficiency coexisting with adequate or elevated total body iron stores. Oral iron supplementation in this context faces active suppression of absorption at the enterocyte level. The gut cannot absorb what hepcidin will not release.

This dynamic has direct clinical implications for iron management that are independent of the gut barrier dysfunction and the dysbiosis picture, though both compound it. It explains the failure of standard oral iron approaches in this patient and contextualizes the decision to use intravenous iron — a decision that bypassed the absorption barrier entirely but with consequences documented in the Iron Dysbiosis Reference.

The hepcidin-iron dynamic is not an intervention target in itself. It is a systemic feature of chronic autoimmune inflammatory load that must be understood when making any decisions about iron management in this patient.

IV. The Locked Dysbiotic Attractor State

Baseline — October 2022

The October 2022 16S metagenomics test documents the pre-collapse microbiome: Proteobacteria 3.8%, Faecalibacterium prausnitzii 14.6% — within or above normal range for a healthy Western microbiome — Blautia 7.3%, Roseburia 5.1%. A genuinely commensal-dominated community with meaningful anti-inflammatory and butyrate-producing capacity. Not pristine — Akkermansia was absent, some pathobionts were present at low levels — but functional. The clinical picture corroborates that reading: helminthic therapy was producing meaningful benefit, inflammatory markers were normalized, microscopic colitis symptoms were in remission.

The Collapse

Two high-dose intravenous iron infusions — October 17, 2023 and February 22, 2024 — triggered catastrophic microbiome collapse. The mechanism and evidence are documented in the Iron Dysbiosis Reference. The result was a state transition of categorical magnitude, not a worsening on a continuum.

August 2024 — Post-Collapse State

Shotgun metagenomics via Thorne platform: Proteobacteria 86.7%, Enterobacteriaceae 81.9% — both at the 99.9th percentile. Faecalibacterium collapsed from 14.6% to the 2.3rd percentile. Roseburia from 5.1% to the 0.9th percentile. Blautia from 7.3% to the 11.8th percentile. Akkermansia remained negligible. Gut dysbiosis score 89.2, intestinal permeability score 83.2, both high risk. The December 2025 colonoscopy documented yellow-brown adherent mucosal biofilm in the ascending colon and splenic flexure — endoscopic evidence of the pathogen-dominated state.

The Locked State — Confirmed

September 2025 repeat shotgun metagenomics: Proteobacteria 79.24%, Enterobacteriaceae 72.51% — still at the 99.9th percentile. The dominant species had shifted: Klebsiella, prominent in 2024, had collapsed; Enterobacter, Pseudomonas, and other opportunists expanded to fill the space. Faecalibacterium, Roseburia, and Akkermansia remained negligible throughout.

In the intervening year, sustained high-quality intervention had been applied — dietary optimization, strategic and varied fiber supplementation, targeted probiotics. The community restructured internally — pathogen substitution within the Enterobacteriaceae — while maintaining the same overall pathological architecture and commensal absence. Movement without improvement is the behavioral signature of a locked attractor state. A system that is simply dysbiotic and untreated drifts. A system in a locked attractor state responds to intervention by reorganizing within the pathological configuration rather than moving toward a prior healthy state.

Why the State Locks

Pathogenic Enterobacteriaceae are not simply outcompeting commensals. They are actively maintaining conditions hostile to commensal recovery. They shift the gut environment toward aerobic conditions that obligate anaerobic commensals cannot survive. Biofilm formation provides physical protection against host immune responses and environmental intervention. The community has reorganized around a new stable state.

V. The Gut-Vagus Connection

The gut and CNS systems are coupled bidirectionally through the vagus nerve, which is the primary communication channel between gut and brain.

Dysbiotic microbiomes produce metabolites — including secondary bile acids, short-chain fatty acids at depleted levels, and various bacterial products — that directly impair vagal afferent signaling. Reduced afferent input diminishes the cholinergic anti-inflammatory reflex arc, reducing efferent anti-inflammatory output. The gut dysbiosis is therefore not only a source of inflammatory drive through LPS translocation — it is simultaneously impairing the primary neural mechanism by which that drive would be modulated.

The result is a self-reinforcing coupling: the compromised gut drives inflammation that the compromised vagal pathway cannot adequately suppress, while the dysbiotic state continues to impair vagal afferent signaling that would otherwise help maintain the cholinergic anti-inflammatory reflex. The two failures compound each other continuously.

This coupling is why the CNS intervention — VNS — and the gut intervention — whatever clinical support pathway ultimately addresses the locked dysbiotic state — are not alternatives. They address different sides of the same coupled failure.

Cross-References

The following documents are part of the master reference system and should be read alongside this document:

• Constitutional CNS Document — the CNS system and its coupling with the gut picture
• Iron Dysbiosis Reference — the iron trigger, collapse mechanism, locked state evidence, personal statement
• Vagal Tone Deficit Mechanistic Reference — the gut-vagus connection in detail, five-factor cumulative vagal deficit
• SetPoint VNS Responder Analysis — Assessment based on truly unknowable response in this system
• Helminthic Therapy Reference — current intervention status and relationship to the gut picture
• Pharmacological Phenotype — amplified medication response pattern, sensitization threshold, PRN constraint, permanently foreclosed agents, clinical safety implications
• Neurological Pattern Reference — HPA axis dysregulation as possible CNS-origin downstream consequence

This document reflects mechanistic relationships and personal hypotheses based on documented history and current research. It is a thinking tool, not a clinical record. 20260520